

# SMT within MOLTO's hybrid translation system

Cristina España-Bonet

Universitat Politècnica de Catalunya, TALP Research Center

–GF Summer School–

Barcelona, August 25th, 2011


# SMT within MOLTO's hybrid translation system

## *Overview*

- 1 General view
- 2 Baselines
- 3 Hybrid systems
- 4 Conclusions

# General view

## *Hybridisation: Baseline systems*



## GF System

- Parse
- Apply patents **grammar**
- Linearise

## Patents **grammar**

- **General** structure grammar
- **Compounds** grammar

## SMT baseline, Standard In-Domain System

- **Language model:** 5-gram interpolated Kneser-Ney discounting, SRILM Toolkit
- **Alignments:** GIZA++ Toolkit
- **Translation model:** Moses package
- **Weights optimization:** MERT against BLEU
- **Decoder:** Moses
- **Evaluation:** Asiya

## CLEF-IP 2010 Collection

Extract of the MAREC dataset, containing over 2.6 million patent documents pertaining to 1.3 million patents from the EPO with some content in English, German and French.

# Baselines

## A Patent document

### Patent document, **IPC** classification.

```
-<patent-document uid="EP-1738753-B1" country="EP" doc-number="1738753" kind="B1" lang="EN" date="20080423" family-id="37453347"
date-produced="20100220" status="new">
-<bibliographic-data>
-<publication-reference fvid="88724218" uid="EP-1738753-B1" status="new">
-<document-id status="new" format="original">
<country status="new">EP</country>
<doc-number>1738753</doc-number>
<kind>B1</kind>
<date>20080423</date>
<lang>EN</lang>
</document-id>
</publication-reference>
+<application-reference mxw-id="PAPP77683688" uid="EP-06017469-A" load-source="docdb" status="new" is-representative="NO"></application-
reference>
+<priority-claims status="new"></priority-claims>
+<dates-of-public-availability status="new"></dates-of-public-availability>
-<technical-data status="new">
-<classifications-ipc>
<classification-ipc mxw-id="PCL624787575" load-source="docdb" status="new">A61K 31/135 20060101C I20051008RMEP </classification-ipc>
<classification-ipc mxw-id="PCL624787849" load-source="docdb" status="new">A61P 3/04 20060101ALI20051220RMJP </classification-ipc>
<classification-ipc mxw-id="PCL624795950" load-source="docdb" status="new">A61K 31/135 20060101A I20051008RMEP </classification-ipc>
<classification-ipc mxw-id="PCL624799973" load-source="docdb" status="new">A61P 25/20 20060101ALI20051220RMJP </classification-ipc>
<classification-ipc mxw-id="PCL624806558" load-source="docdb" status="new">A61K 31/137 20060101CFI20071018BHEP </classification-ipc>
<classification-ipc mxw-id="PCL624810330" load-source="docdb" status="new">A61K 31/137 20060101AFI20071018BHEP </classification-ipc>
<classification-ipc mxw-id="PCL624820189" load-source="docdb" status="new">A61P 3/00 20060101CLI20051220RMJP </classification-ipc>
<classification-ipc mxw-id="PCL624827390" load-source="docdb" status="new">A61P 25/00 20060101ALI20071018BHEP </classification-ipc>
<classification-ipc mxw-id="PCL624828540" load-source="docdb" status="new">A61P 25/00 20060101CFI20071018BHEP </classification-ipc>
```

### Description, **claims**.

```
<u style="single">Obesity Reduction Test Results</u>
</b>
</heading>
- <p num="p0023">
  The venlafaxine group showed consistent statistically significant mean weight decreases and mean percent decreases from baseline beginning at week 1. Overall, the mean decrease in body weight for the venlafaxine group at week 10 was 7.5 lb with a mean percent decrease from baseline of 3.6%. In contrast, the mean decrease in body weight for the placebo group at week 10 was 1.3 lb with a mean percent decrease from baseline of 0.7%. The body mass index evaluation for the venlafaxine also showed a pattern of decreases similar to that of the weight decreases.
</p>
</description>
- <claims mxw-id="PCLM12825865" lang="DE" load-source="patent-office" status="new">
- <claim id="c-de-01-0001" num="0001">
- <claim-text>
  Verwendung einer Verbindung mit der Formel
  + <chemistry id="chem0006" num="0006"></chemistry>
  in der A eine Komponente der Formel
  + <chemistry id="chem0007" num="0007"></chemistry>
  ist, wobei
  <br/>
  die gestrichelte Linie eine optionale Unsattigung darstellt;
- <claim-text>
  R
  <sub>1</sub>
  Wasserstoff oder Alkyl mit 1 bis 6 Kohlenstoffatomen ist;
</claim-text>
- <claim-text>
  R
  <sub>2</sub>
```





- Patent documents with **translated claims**.  
(not all of them!)
- IPC classification **A61P**.  
Specific therapeutic activity of chemical compounds or medical preparations.

- Patent documents with **translated claims**.  
(not all of them!)
- IPC classification **A61P**.  
Specific therapeutic activity of chemical compounds or medical preparations.

**56000 patents** out of 1.3 million fulfill these demands.  
(**279282** aligned parallel fragments)

Claims are written in a **lawyerish style** and using a very **specific vocabulary** of chemistry, full of **compounds names**.

### Excerpt 1

- The use according to claim 7, wherein said cancer diseases comprise bladder, lung, mamma, melanoma and prostate carcinomas.
- A compound according to claim 1 wherein it is (2S)-2-[(4S)-4-(2,2-difluorovinyl)-2-oxopyrrolidinyl]butanamide.
- The pharmaceutical composition according to claim 1 or 2, wherein said platinum anticancer agent is selected from at least one of the complexes having structures of: **\*\*IMAGE\*\***.

Claims are written in a **lawyerish style** and using a very **specific vocabulary** of chemistry, full of **compounds names**.

### Excerpt 1

- **The use according to claim 7, wherein** said cancer diseases comprise bladder, lung, mamma, melanoma and prostate carcinomas.
- **A compound according to claim 1 wherein** it is (2S)-2-[(4S)-4-(2,2-difluorovinyl)-2-oxopyrrolidinyl]butanamide.
- The pharmaceutical **composition according to claim 1 or 2, wherein said** platinum anticancer agent is selected from at least one of the complexes having structures of: **\*\*IMAGE\*\***.

Claims are written in a **lawyerish style** and using a very **specific vocabulary** of chemistry, full of **compounds names**.

### Excerpt 1

- The use according to claim 7, wherein said cancer diseases comprise **bladder, lung, mamma, melanoma and prostate carcinomas**.
- A compound according to claim 1 wherein it is (2S)-2-[(4S)-4-(2,2-difluorovinyl)-2-oxopyrrolidinyl]butanamide.
- The pharmaceutical composition according to claim 1 or 2, wherein said **platinum anticancer agent** is selected from at least one of the complexes having structures of: **\*\*IMAGE\*\***.

Claims are written in a **lawyerish style** and using a very **specific vocabulary** of chemistry, full of **compounds names**.

### Excerpt 1

- The use according to claim 7, wherein said cancer diseases comprise bladder, lung, mamma, melanoma and prostate carcinomas.
- A compound according to claim 1 wherein it is **(2S)-2-[(4S)-4-(2,2-difluorovinyl)-2-oxopyrrolidinyl]butanamide**.
- The pharmaceutical composition according to claim 1 or 2, wherein said platinum anticancer agent is selected from at least one of the complexes having structures of: **\*\*IMAGE\*\***.

Claims have also **long sentences** and **missing information**.

### Excerpt 2

- Use of compounds of formula I **\*\*IMAGE\*\*** wherein R1 signifies substituted C1-C4-alkylene, whereby the substituents are selected from the group comprising unsubstituted aryloxy or aryloxy mono- to penta-substituted by R5, and unsubstituted pyridyloxy or pyridyloxy mono- to tetra-substituted by R5, whereby the substituents may be the same as one another or different if the number thereof is greater than 1; R2 signifies unsubstituted phenyl or phenyl mono- to penta-substituted by R5, or unsubstituted pyridyl or pyridyl mono- to tetra-substituted by R5; R3 is methyl; R4 signifies hydrogen, C1-C6-alkyl or halogen-C1-C6-alkyl; R5 signifies C1-C6-alkyl, C1-C6-alkoxy, halogen-C1-C6-alkyl, halogen-C1-C6-alkoxy, C2-C6-alkenyl, halogen-C2-C6-alkenyl, C2-C6-alkinyl, halogen-C2-C6-alkinyl, C3-C8-cycloalkyl, C1-C6-alkylcarbonyl, halogen-C1-C6-alkylcarbonyl, C1-C6-alkoxycarbonyl, halogen-C1-C6-alkoxycarbonyl, C1-C6-alkylsulfonyl, C1-C6-alkylsulfinyl, halogen, cyano or nitro; A signifies C(R6)(R7), CH=CH or C=C; R6 and R7 either, independently of one another, signify hydrogen, halogen, C1-C6-alkyl, C1-C6-alkoxy, halogen-C1-C6-alkyl, halogen-C1-C6-alkoxy or C3-C6-cycloalkyl; or together signify C2-C6-alkylene; R8 and R9 are hydrogen; m and n, independently...of one other, are 0 or 1; and optionally enantiomers thereof, with the proviso that if m is 0 then R1 is retained; in the preparation of a pharmaceutical composition for the control of endoparasitic helminths in warm-blooded productive livestock and domestic animals.

# Baselines

*SMT baseline, evaluation*

## BLEU

	EN2DE	DE2EN	EN2FR	FR2EN	DE2FR	FR2DE
<b>Bing</b>	0.33	0.43	0.43	0.45	0.20	0.24
<b>Google</b>	0.45	0.58	0.53	0.62	0.43	0.39
<b>Domain</b>	<b>0.58</b>	<b>0.65</b>	<b>0.62</b>	<b>0.70</b>	<b>0.56</b>	<b>0.53</b>



# Baselines

## *English-German Translations, scores*

METRIC	DE2EN			EN2DE		
	Bing	Google	Domain	Bing	Google	Domain
1-WER	0.52	0.64	<b>0.72</b>	0.42	0.51	<b>0.69</b>
1-PER	0.66	0.76	<b>0.82</b>	0.56	0.64	<b>0.77</b>
1-TER	0.59	0.67	<b>0.76</b>	0.45	0.53	<b>0.71</b>
BLEU	0.43	0.58	<b>0.65</b>	0.33	0.45	<b>0.58</b>
NIST	8.25	9.67	<b>10.12</b>	6.53	8.05	<b>9.40</b>
ROUGE-W	0.40	0.48	<b>0.52</b>	0.34	0.41	<b>0.48</b>
GTM-2	0.30	0.40	<b>0.47</b>	0.25	0.32	<b>0.43</b>
METEOR-pa	0.60	0.69	<b>0.74</b>	0.36	0.45	<b>0.57</b>
ULC	0.09	0.29	<b>0.41</b>	0.03	0.19	<b>0.43</b>

Why such good scores?

---

<b>DE</b>	Verwendung nach Anspruch 23 , worin das molare Verhältnis von Arginin zu Ibuprofen 0,60 : 1 beträgt .
<b>EN</b>	The use of claim 23 , wherein the molar ratio of arginine to ibuprofen is 0.60 : 1 .

---

Why such good scores?

---

**DE**      Verwendung nach Anspruch 23 , worin das molare Verhältnis von Arginin zu Ibuprofen 0,60 : 1 beträgt .

**EN**      **The use** of claim 23 , wherein the molar ratio of arginine to ibuprofen is 0.60 : 1 .

---

**Domain**    The use of claim 23 , wherein the molar ratio of arginine to ibuprofen is 0.60 : 1 .

**Google**    The **method** of claim 23 , wherein the molar ratio of arginine to ibuprofen 0.60 : 1 **is** .

**Bing**      ~~The~~ Use of claim 23 , wherein the molar ratio of arginine to ibuprofen is 0.60 : 1 .

---

What's wrong?

---

<b>DE</b>	(±)-N-(3-Aminopropyl)-N,N-dimethyl-2,3-bis(syn-9-tetradecenyl-1-oxy)-1-propanaminiumbromid
<b>EN</b>	(±)-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(syn-9-tetradecenyl-1-oxy)-1-propanaminium bromide

---

What's wrong?

---

<b>DE</b>	(±)-N-(3-Aminopropyl)-N,N-dimethyl-2,3-bis(syn-9-tetradecenyloxy)-1-propanaminiumbromid
<b>EN</b>	(±)-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(syn-9-tetradecenyloxy)-1-propanaminium bromide

---

<b>Domain</b>	(±)-N-(3-Aminopropyl)-N,N-dimethyl-2,3-bis(syn-9-tetradecenyloxy)-1-propanaminiumbromid
<b>Google</b>	(±)-N-(3-aminopropyl)-N , N-dimethyl-2 , 3-bis (syn-9-tetradecenyloxy) is 1- propanaminiumbromid
<b>Bing</b>	(±)-N-(3-Aminopropyl)-N,N-dimethyl-2,3-bis(syn-9-tetradecenyloxy)-1-propanaminiumbromid

---

# Baselines

## *English-French Translations, scores*

METRIC	FR2EN			EN2FR		
	Bing	Google	Domain	Bing	Google	Domain
1-WER	0.54	0.66	<b>0.78</b>	0.57	0.63	<b>0.73</b>
1-PER	0.71	0.78	<b>0.86</b>	0.68	0.75	<b>0.82</b>
1-TER	0.59	0.70	<b>0.80</b>	0.60	0.66	<b>0.74</b>
BLEU	0.45	0.62	<b>0.70</b>	0.43	0.53	<b>0.62</b>
NIST	8.52	10.01	<b>10.86</b>	8.39	9.21	<b>9.96</b>
ROUGE-W	0.41	0.50	<b>0.54</b>	0.39	0.45	<b>0.49</b>
GTM-2	0.32	0.43	<b>0.53</b>	0.31	0.36	<b>0.45</b>
METEOR-pa	0.61	0.72	<b>0.77</b>	0.57	0.65	<b>0.71</b>
ULC	0.07	0.28	<b>0.44</b>	0.10	0.23	<b>0.39</b>

# Baselines

## German-French Translations, scores

METRIC	DE2FR			FR2DE		
	Bing	Google	Domain	Bing	Google	Domain
1-WER	0.42	0.52	<b>0.76</b>	0.30	0.43	<b>0.65</b>
1-PER	0.58	0.68	<b>0.77</b>	0.46	0.59	<b>0.74</b>
1-TER	0.47	0.56	<b>0.68</b>	0.32	0.46	<b>0.66</b>
BLEU	0.29	0.43	<b>0.56</b>	0.24	0.39	<b>0.53</b>
NIST	6.72	8.21	<b>9.10</b>	5.35	7.30	<b>8.88</b>
ROUGE-W	0.31	0.38	<b>0.45</b>	0.29	0.37	<b>0.44</b>
GTM-2	0.24	0.30	<b>0.41</b>	0.21	0.28	<b>0.41</b>
METEOR-pa	0.45	0.56	<b>0.64</b>	0.26	0.39	<b>0.51</b>
ULC	0.03	0.22	<b>0.41</b>	-0.03	0.19	<b>0.44</b>

### **Google**

Few OOVs but tokenization problems with compounds.

### **Bing**

Lack of specific vocabulary.

### **In-domain SMT**

Try to solve the problems of the general systems, but still:

- Improve compound detector.
- Fix structures are translated different depending on the vocabulary.



### **GF Pros** (as compared to SMT)

- Capture **long distance** relations and reordering.
- Better **grammaticality**.

### **GF Cons** (as compared to SMT)

- Dependence on the **initial parsing**.
- Lexical transfer **disambiguation**.
- High development **cost** of the grammars and associated resources.

# Hybrid systems

*Two hybridisation approaches*

**Statistical MT** can alleviate some of the **RBMT** flaws

# Hybrid systems

*Two hybridisation approaches*

**Rule-based MT** can alleviate some of the **SMT** flaws

**Rule-based MT** can alleviate some of the **SMT** flaws

**Who leads** the hybrid model?

**SMT.** GF is used to enrich the “translation model” of the SMT system (known approach)

**RBMT.** SMT is used to provide confidence scored translation options to the RBMT target tree (novel)

## Hard integration

Force fixed GF translations within a SMT system.

- ✓ Straightforward to implement from the SMT pov.
- ◇ Need of GF partial translations.
- ✗ There is no interaction between GF and SMT.

## **SMT leads translation, GF complements**

Complement the SMT translation table with GF options.

- If GF is able to generate Giza-like alignments, phrases can be extracted in the SMT way and we can combine translation tables.

### **GF alignments**

- Based on the relation between the concrete syntaxes and the abstract syntax.
- Many-to-many.
- Semantic wrt. abstract syntax.

### **SMT alignments**

- Based on corpus occurrences.
- One-to-many.

### **From many-to-many to one-to-many**

You want\_to\_go to the\_nearest park  
(0) (1) (2) (3) (4)

Quieres ir al parque mas cercano  
(0) (1)(2) (3) (4) (5)

1-0 1-1 2-2 3-4 3-5 4-3

(alignments from Phrasebook grammar)



# Conclusions

## *Summary*

- The first step towards hybridisation has been building individual systems.
- SMT already achieves an acceptable translation quality.
- However, the combination of different approaches to translation can help to solve the observed translation errors.
- Several ways to combine GF and SMT can (and should!) be applied.

# SMT within MOLTO's hybrid translation system

Cristina España-Bonet

Universitat Politècnica de Catalunya, TALP Research Center

–GF Summer School–

Barcelona, August 25th, 2011

### **Phrasebook grammar** (toy example)

- Syntetic corpus generation.
- Parallel corpus with 200 sentences.
- Insignificant for SMT (by 2-3 orders of magnitude!).
- Null intersection with SMT corpora.

### **Patents grammar**

- Needed for real experiments.

# Conclusions

## *Hybrid SMT-RBMT: Experiments*

Translation Table, core of an SMT system:

source language ||| target language ||| probabilities

...

quite a burden ||| un estorbo muy grande ||| 0.25 1.57587e-06 0.25 3.57895e-12 2.718

quite a burden ||| un estorbo muy ||| 0.25 1.57587e-06 0.25 8.38161e-08 2.718

quite a challenge but we ||| todo un reto , pero lo ||| 0.5 6.64558e-05 1 1.46764e-06 2.718

quite a challenge but ||| todo un reto , pero ||| 0.5 0.00179307 1 9.70607e-05 2.718

quite a challenge ||| todo un reto , ||| 0.5 0.002396 0.5 0.000190619 2.718

quite a challenge ||| todo un reto ||| 0.333333 0.002396 0.5 0.00244338 2.718

quite a considerable delay ||| un retraso muy considerable ||| 0.333333 2.91692e-05 ...

quite a contribution towards ||| una importante contribución en lo ||| 0.25 9.69758e-07 ...

quite a contribution towards ||| una importante contribución en ||| 0.142857 9.69758e-07 ...

quite a difference whether ||| muy diferente ||| 0.0344828 8.29695e-09 1 0.0013126 2.718

quite a difference ||| muy diferente ||| 0.0344828 1.38144e-05 1 0.0013126 2.718

...

**GF** scored partial output as **new features** in SMT decoding.

$$\log P(e|f) \sim \lambda_{lm} \log P(e) + \lambda_g \log P(f|e) + \lambda_d \log P(e|f) \\ + \lambda_{di} \log P_{di}(e, f) + \lambda_w \log w(e) + \lambda_{GF} \log P_{GF}(e|f)$$

quite a challenge ||| todo un reto ||| 0.333 0.002 0.5 0.002 2.718  **$\log P_{GF}(e|f)$**

Requirements:

- GF predictions have to be probabilistic.
- Phrase pairs without prediction must be complemented.

## **RBMT leads translation, SMT decodes**

Complement the RBMT translation structure with SMT options.

### ■ **SMatxinT**

Approach being applied for **Basque-to-Spanish** with the RBMT system Matxin.

OpenMT-2 Spanish Research Project  
UPC+EHU collaboration

# Conclusions

## *An hybrid RBMT-SMT system: SMatxinT, methodology*

- The RBMT system must parse and translate the input sentence.
- Phrases and segmentation are those given by the RBMT system.
- Each segment (and up) is sent to a generic SMT to provide more partial translations.
- A Moses-like decoder is fed with the resulting phrases to search for the highest scored translation.
- This statistical decoder performs no reordering and uses very simple features.

## Current results

- Large difference between in-domain and out-of-domain scenarios.
- Results are at most close to SMT system.
- Oracles show large room for improvement.
- RBMT phrases are underused.
- Current features are not distinctive enough.



### **SMatxinT vs. MOLTO**

#### **General translator vs. in-domain translator**

With SMatxinT results are better for out-of-domain tests, where the difference between SMT and RBMT systems is less important, but systems (specially SMT) have a lower quality.

### **Matxin vs. GF**

#### **General grammar vs. in-domain grammar**

With MOLTO both systems will be in-domain, so they are expected to be high quality. Improvements here will be over already good translations.

### Learning GF grammars

---

Abstract syntax	Like She He	Grammarians
English example	she likes him	Grammarians
German translation	er gefällt ihr	<b>SMT</b>
Resource tree	mkCl he <sub>PRON</sub> gefallen <sub>V2</sub> she <sub>PRON</sub>	GF parser
Syntax rule	Like x y = mkCl y gefallen <sub>V2</sub> x	Variables renamed

---

- SMT of short and frequent sentences is good

# Conclusions

*Statistical extension of GF grammar, application*

- Applied to the **Phrasebook grammar**
- **Languages:** Danish, Dutch, German, Norwegian
- Phrasebook **demo:**  
<http://www.molto-project.eu/demo/phrasebook>